Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...

The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.

which has already got a biosimilar to Roche’s Avastin (bevacizumab) cancer drug backed by the FDA. Amgen already has a biosimilar of AbbVie’s Humira (adalimumab) approved in the US ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the ...

The drugs treat conditions such as diabetes and cancer, and seniors across the country rely on ... including those that have ...

First, the liver cancer treatment 'TULBEGIO ... a boom in biosimilars is expected, so this year, even more domestically produced new drugs and pharmaceuticals are expected to receive FDA approval ...

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks ...

Johnson & Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit, with robust sales of cancer treatments leading the charge ...